Go back

GlaxoSmithKline suffers losses after lung-drug trial

UK pharmaceutical company GlaxoSmithKline saw its biggest drop in shares for nearly three years after tests concluded that there was “no statistical difference” between one of its new and an existing lung drugs, reported the Daily Telegraph on 10 January.

The 12-week trial—showing that GSK’s new drug Relovair was no more effective than its existing drug Advair—caused the company’s shares to drop by 62p to £14.35.

This article is only available to Research Professional News subscribers or Pivot-RP users.

If you are a Research Professional News subscriber you can log in and view the article via this link

Pivot-RP users can log in and view the article via this link.